Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...
pharmaphorum3d
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Buy, Sell, Or Hold MRNA Stock?
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.